Perhaps right, but $11m available funding at end of quarter, and...

Perhaps right, but $11m available funding at end of quarter, and considerably reduced expenses with the sale of Neutraceuticals to PharmaCare. Now they also have a cash flow stream from R&D rebates on o/s expenses coming in each year.

Either way, if they do still need to CR in the future, they absolutely would have needed to before this boon - an extra $12m over 3 years remains a far better position to be in than we were pre announcement.

Price action might not reflect it, but the shares should be worth a few cents more today on this news.